← Back to patent-cliff list
QLC-1101
Tier C — Watch / tradeQLC-1101
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：KRAS G12D
Indications (approved)：Solid tumour, Non-small cell lung cancer, Colorectal cancer, Pancreatic cancer
Regional status
US
-
EU
-
China
Phase II
2025-06-13
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of QLC-1101?
Approved indications include: Solid tumour, Non-small cell lung cancer, Colorectal cancer, Pancreatic cancer.
When does the QLC-1101 patent expire?
No public expiry year is available for QLC-1101 yet; this page updates once verified.
How do I get a quote for QLC-1101 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30